Carregant...
U.S. Food and Drug Administration–Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis
OBJECTIVES: We sought to determine if use of a poly (ADP-ribose) polymerase (PARP) inhibitor is cost effective for maintenance treatment of platinum-sensitive recurrent ovarian cancer. METHODS: A decision analysis model compared 4 maintenance strategies: 1) Observation 2) BRCA germline mutation test...
Guardat en:
| Publicat a: | Obstet Gynecol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7181403/ https://ncbi.nlm.nih.gov/pubmed/30870286 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/AOG.0000000000003171 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|